TMJ Syndrome with Severe Localized Pain in Disc Displacement Without Reduction

This protocol addresses the specialist secondary care management of temporomandibular joint (TMJ) syndrome in patients presenting with disc displacement without reduction and severe localized TMJ pain.

Clinical Scenario

Evidence supports escalated pharmacological management in a specific sub-group: patients with disc displacement without reduction who present with severe localized temporomandibular joint pain. This level of intervention is restricted to the specialist secondary care setting — it is not a primary care approach.

Treatment Approach

Management involves a combination pharmacological strategy. In addition to other measures, a short course of oral corticosteroid therapy is part of the approach, subject to clinical contraindications and relevant prescribing guidance. Patients at elevated risk of gastrointestinal complications may require additional co-prescribed gastroprotection for the duration of treatment. The complete sequenced regimen — including clinical criteria, sequencing, and all components — is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

The evidence suggests that oral corticosteroid use in the management of TMD is restricted to the specialist, secondary care setting for management of some disc displacements without reduction presenting with severe localized TMJ pain.

In such instances in addition to diazepam, a short course of oral prednisolone can be prescribed, subject to no contraindications and following NICE prescribing information for oral corticosteroids available here.

Individuals being prescribed prednisolone who are at elevated risk of gastrointestinal (GI) bleeding or dyspepsia (Table 9) should be co-prescribed a proton-pump inhibitor (Lansoprazole 15 mg OD or Gastro-resistant omeprazole capsules 20mg OD) for the duration of the course.

As short course (<3 weeks) can be stopped abruptly i.e., Tapered reduction not required.

View source ↗